{"ModuleTitle": "Company Description", "CompanyName": "Jazz Pharmaceuticals plc", "Symbol": "JAZZ", "Address": "FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN, 4, Ireland", "Phone": "353-1-634-7800", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "Europe", "CompanyDescription": "Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to\r\ndeveloping life-changing medicines for people with serious diseases - often with\r\nlimited or no options. We have a diverse portfolio of marketed medicines and\r\nnovel product candidates, from early- to late-stage development, in key\r\ntherapeutic areas. Our focus is in neuroscience, including sleep medicine and\r\nmovement disorders, and in oncology, including hematologic and solid tumors.\r\nOur lead marketed products are:\r\n*      Xyrem\u00ae (sodium oxybate) oral solution, the only product approved by the   \r\n       U.S. Food and Drug Administration, or FDA, and marketed in the U.S. for   \r\n       the treatment of both cataplexy and excessive daytime sleepiness, or EDS, \r\n       in both adult and pediatric patients with narcolepsy;                     \r\n\r\n\r\n*      Sunosi\u00ae (solriamfetol), a product approved by the FDA and marketed in the \r\n       U.S.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f25%2f0001232524-20-000016.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Bruce C. Cozadd", "title": "Chairman & Chief Executive Officer"}, {"name": "Daniel N. Swisher", "title": "President & Chief Operating Officer"}, {"name": "Finbar Larkin", "title": "Senior Vice President-Technical Operations"}, {"name": "RenTe D. Gal\u00df", "title": "Chief Financial Officer & Executive Vice President"}, {"name": "Robert Iannone", "title": "Executive Vice President-Research & Development"}], "Number_of_employees": ["1,210"], "Subsidiaries": ["NO INFO"]}